Raising FY26 EPS guidance to $10.15-$10.35, 23-26% growth
Cardinal Health delivered another strong quarter with all five segments growing profit at least double digits, raised full-year EPS guidance for the second time to $10.15-$10.35 driven by pharma strength and continued progress in the GMPD turnaround. The company highlighted broad-based demand, particularly in specialty, theranostics, and at-home solutions, while also noting some near-term headwinds such as tariff impacts and lapping of new customer revenues in the second half. All five operating segments delivered double-digit or better profit growth in Q2 FY26, demonstrating balanced portfolio performance.
Buzzberg readRaising FY26 EPS guidance to $10.15-$10.35, 23-26% growthCardinal Health delivered another strong quarter with all five segments growing profit at least double digits, raised full-year EPS guidance for the second time to $10.15-$10.35 driven by pharma strength and continued progress in the GMPD turnaround. The company highlighted broad-based demand, particularly in specialty, theranostics, and at-home solutions, while also noting some near-term headwinds such as tariff impacts and lapping of new customer revenues in the second half. All five operating segments delivered double-digit or better profit growth in Q2 FY26, demonstrating balanced portfolio performance.Read full analysisCollapse analysis
Cardinal Health delivered another strong quarter with all five segments growing profit at least double digits, raised full-year EPS guidance for the second time to $10.15-$10.35 driven by pharma strength and continued progress in the GMPD turnaround. The company highlighted broad-based demand, particularly in specialty, theranostics, and at-home solutions, while also noting some near-term headwinds such as tariff impacts and lapping of new customer revenues in the second half. All five operating segments delivered double-digit or better profit growth in Q2 FY26, demonstrating balanced portfolio performance.
Pharma & Specialty segment profit rose 29% to $687M, driven by brand/specialty products, MSO platforms, and strong generic unit growth.
GLP-1 sales contributed approximately 6% of revenue growth in the quarter.
GMPD segment profit improved to $37M with Cardinal Health brand portfolio growing 10% in the US, though 3-4 pts of that growth was due to distributor restocking timing.
Revenue$65.441B
reported
EPS$2.63
reported
Gross margin3.38%
reported
Op margin1.08%
reported
What changed this quarter
01
Guidance
Raising FY26 EPS guidance to $10.15-$10.35, 23-26% growth
Guidance tone
02
Specialty
Specialty revenue to surpass $50 billion in fiscal 26
All five operating segments delivered double-digit or better profit growth in Q2 FY26, demonstrating balanced portfolio performance.
03
Growth
Five operating segments all delivered double-digit profit growth
Pharma & Specialty segment profit rose 29% to $687M, driven by brand/specialty products, MSO platforms, and strong generic unit growth.
04
Turnaround
GMDP segment profit raised to ~$150 million, turnaround progressing
GLP-1 sales contributed approximately 6% of revenue growth in the quarter.
AI, capex & demand read
AI
Platform & monetization
AI is not discussed in this transcript.
Demand
Bookings & conversion
Management raised full-year EPS guidance for the second time this year to $10.15-$10.35, representing 23-26% growth, driven by broad-based demand strength and strong operational execution across all five segments.
Capex
Investment and capacity
Management is investing in technology infrastructure (e.g., Vantus HQ eCommerce platform, Total View Insights) and capital expenditures to support organic growth initiatives, with year-to-date capex of approximately $240 million and a full-year guidance of $600-$650 million. They are also investing in distribution network automation, cyclotron capacity, and GMPD network improvements.
Tone · Confident
Management repeatedly highlights strong execution, raised guidance twice, and expresses confidence in the resilience and momentum of the business.
Supply-chain alpha
A1
Cardinal Health brands in the GMPD segment saw 3-4 percentage points of growth from timing of inventory restocking by other distributors, which will offset in Q3.
“It is worth noting that we estimate three to four percentage points of this growth in the quarter was driven by the timing of inventory restocking by other distributors, which we anticipate offsetting in Q3.”
Cardinal Health brands in the GMPD segment saw 3-4 percentage points of growth from timing of inventory restocking by other distributors, which will offset in Q3. — Indicates temporary channel fill dynamics in the medical supply chain; peers may see similar inventory timing effects.
… such as the Vantus HQ eCommerce platform, to drive customer efficiency and streamline our operations, which directly supports our margin profile. Moving to the GMPD segment. Revenue increased 3% to $3.3 billion, driven by volume growth from our existing customer base. We were particularly pleased with the performance of our Cardinal Health brand portfolio, which saw revenue growth of 10% in the United States. It is worth noting that we estimate three to four percentage points of this growth in the quarter was driven by the timing of inventory restocking by other distributors, which we anticipate offsetting in Q3. Segment profit for GMPD increased to $37 million compared to $18 million in the prior year period. This improvement was driven by volume growth from existing customers and the realization of benefits from our cost optimization initiatives. These positive drivers were partially offset by the adverse net impact of tariffs. Despite the tariff headwind, the segment's transition from past challenges to solid profitability is evident, and we remain committed to the improvement plan initiatives that focus on growing Cardinal Health brand, enhancing our supply chain, and …
🍪 Cookies
We use cookies to operate this site and for analytics. Declining won't affect your access to content.